Q4 is a reminder that Ascelia ticked some essential boxes during 2024, including completing a succes...
Redeye comments on EG7’s Q4-results where the overall outcome was close to our expectations, adjuste...
Redeye states Gapwaves Q4 2024 report was better than expected Redeye Research Estimates and the con...
Redeye retains its positive view of Hexatronic following the Q4 report, showing a stable quarter in ...
Redeye updates its estimates following CTEK’s Q4 report, which was largely impacted by General Motor...
SRV’s Q4/24 figures largely matched our expectations, yet the 2025 outlook left much to be desired.
Redeye revised its update on Enea after uncovering errors in its financial model.
The company downgraded its 2024 guidance in December, dampening expectations for the Q4 numbers.
Redeye reinforces its positive view of Transtema following a strong Q4, where Sweden improved substa...
In-line Q4 report, increased focus on sales growth in 2025 We cut '25e-'26e EBITA by 5-2% on lower m...
On February 6th, Eevia Health published the Company’s quarterly report for Q4-24.
Redeye returns to covering Sedana Medical and presents its preview for the company’s Q4 report, whic...
LapWall's fourth quarter performance was solid, despite net sales falling 13% y/y.
SRV's net sales in Q4 amounted to EUR 209.1m, slightly above our estimate of EUR 196.
Redeye presents its preview for Devyser’s Q4 2024 report, due on February 13.
Better Collective has released preliminary results for Q4 which were stronger than expected, support...
Redeye continues to be positive to Bredband2 following a Q4 report in line with our estimates, posti...
Sales and EBITA in line, c. 6% organic growth y-o-y Better customer intake, +1,900 q-o-q (ABG +1,000...
Redeye comments on Alligator Bioscience's end of phase II meeting with the American regulatory autho...
ASTar was awarded the tender at Cliniques Universitaires Saint-Luc in Brussels.
